Recombinant multi-species TGFBR3L protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine TGFBR3L protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Predicted to enable glycosaminoglycan binding activity; transforming growth factor beta-activated receptor activity; and type II transforming growth factor beta receptor binding activity. Predicted to contribute to transforming growth factor beta binding activity. Predicted to be involved in several processes, including blood vessel morphogenesis; regulation of transforming growth factor beta receptor signaling pathway; and transforming growth factor beta receptor signaling pathway. Predicted to be integral component of membrane. Predicted to be active in cell surface and extracellular space. [provided by Alliance of Genome Resources, Apr 2022]
The Alternative Names of target: GEMP,Gm14378,TGF-beta receptor type-3-like protein (TGFR-3L),TGFBR3L,TGFR-3L,Tgfbr3l,Transforming growth factor-beta receptor type 3-like protein,Transforming growth factor-beta receptor type III-like protein (TGF-beta receptor type III-like protein)

Target products collectionGo to TGFBR3L products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP1911-Ag-1/ GM-Tg-hg-IP1911-Ag-2 Human TGFBR3L protein Human
GM-Tg-rg-IP1911-Ag-1/ GM-Tg-rg-IP1911-Ag-2 Rat TGFBR3L protein Rat
GM-Tg-mg-IP1911-Ag-1/ GM-Tg-mg-IP1911-Ag-2 Mouse TGFBR3L protein Mouse
GM-Tg-cynog-IP1911-Ag-1/ GM-Tg-cynog-IP1911-Ag-2 Cynomolgus/Rhesus macaque TGFBR3L protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP1911-Ag-1/ GM-Tg-felg-IP1911-Ag-2 Feline TGFBR3L protein Feline
GM-Tg-cang-IP1911-Ag-1/ GM-Tg-cang-IP1911-Ag-2 Canine TGFBR3L protein Canine
GM-Tg-bovg-IP1911-Ag-1/ GM-Tg-bovg-IP1911-Ag-2 Bovine TGFBR3L protein Bovine
GM-Tg-equg-IP1911-Ag-1/ GM-Tg-equg-IP1911-Ag-2 Equine TGFBR3L protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP1911-Ag-1/ GM-Tg-hg-IP1911-Ag-2; GM-Tg-rg-IP1911-Ag-1/ GM-Tg-rg-IP1911-Ag-2;
GM-Tg-mg-IP1911-Ag-1/ GM-Tg-mg-IP1911-Ag-2; GM-Tg-cynog-IP1911-Ag-1/ GM-Tg-cynog-IP1911-Ag-2;
GM-Tg-felg-IP1911-Ag-1/ GM-Tg-felg-IP1911-Ag-2; GM-Tg-cang-IP1911-Ag-1/ GM-Tg-cang-IP1911-Ag-2;
GM-Tg-bovg-IP1911-Ag-1/ GM-Tg-bovg-IP1911-Ag-2; GM-Tg-equg-IP1911-Ag-1/ GM-Tg-equg-IP1911-Ag-2
Products Name TGFBR3L protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name TGFBR3L
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine TGFBR3L protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.